NVO Stock Today, February 04: Shares Plunge on 2026 Sales Cut
Novo Nordisk stock dropped sharply today after management cut 2026 revenue guidance by 5–13%, citing strong U.S. pricing pressure, planned Wegovy price cuts, patent headwinds for semaglutide, and tougher competition. The ADR NVO fell heavily intraday as investors reset GLP-1 profit expectations. A DKK 15 billion buyback did not steady sentiment. We explain the drivers, the price action, and what this means for German portfolios, with practical levels and next catalysts to watch.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →